Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan.
Gen Hosp Psychiatry. 2024 Jul-Aug;89:75-83. doi: 10.1016/j.genhosppsych.2024.05.001. Epub 2024 May 7.
Evidence suggests that inflammatory processes play a role in the pathophysiology of schizophrenia. Statins exert anti-inflammatory and antioxidant effects and may be effective in improving the symptoms of schizophrenia. This study explored whether statins, as an adjunctive therapy, can alleviate the symptoms of schizophrenia.
PubMed, EMBASE, and the Cochrane Library were searched for articles published up to March 2023. The risk-of-bias tool for randomized trials was used to assess study quality. Two researchers independently assessed the risks of bias and extracted data. Pooled data on Positive and Negative Syndrome Scale (PANSS) scores were analyzed. A random-effects model was employed to calculate pooled effect sizes. Statistical heterogeneity across studies was assessed using the I statistic. All analyses were performed using RevMan5 and Comprehensive Meta-Analysis software.
Nine trials enrolling 533 patients in total were included. Add-on statin therapy was found to be associated with a significantly better total PANSS score [standardized mean difference (SMD) = -0.42, 95% confidence interval (CI) -0.75 to -0.09, I = 72%; P = 0.01] and PANSS negative subscale score (SMD = -0.26, 95% CI -0.45 to -0.07, I = 0%; P = 0.009) in comparison with placebo. However, add-on statin therapy did not appear to improve scores for the PANSS positive and general subscales at the study-defined endpoint (6-24 weeks).
Our meta-analysis indicates that adjunctive statin therapy may confer benefits in ameliorating PANSS negative and total scores. It needs more solid data to confirm the results are related to clinical improvement and functioning.
有证据表明，炎症过程在精神分裂症的病理生理学中起作用。他汀类药物具有抗炎和抗氧化作用，可能有助于改善精神分裂症的症状。本研究探讨了他汀类药物作为辅助治疗是否可以减轻精神分裂症的症状。
检索了截至 2023 年 3 月发表的 PubMed、EMBASE 和 Cochrane 图书馆的文章。使用随机试验风险评估工具评估研究质量。两位研究人员独立评估偏倚风险并提取数据。对阳性和阴性症状量表 (PANSS) 评分的汇总数据进行分析。采用随机效应模型计算汇总效应量。使用 I ²统计评估研究间的统计异质性。所有分析均使用 RevMan5 和 Comprehensive Meta-Analysis 软件进行。
共有 9 项试验纳入了 533 名患者。加用他汀类药物治疗与总 PANSS 评分显著改善相关[标准化均数差 (SMD) = -0.42，95%置信区间 (CI) -0.75 至 -0.09，I² = 72%；P = 0.01]和 PANSS 阴性量表评分(SMD = -0.26，95% CI -0.45 至 -0.07，I² = 0%；P = 0.009)与安慰剂相比。然而，加用他汀类药物治疗似乎并没有改善研究定义的终点(6-24 周)时 PANSS 阳性和一般量表的评分。
我们的荟萃分析表明，辅助他汀类药物治疗可能有助于改善 PANSS 阴性和总分。需要更多确凿的数据来证实这些结果与临床改善和功能有关。
